Table 3.
Relationship Between Glypican-1 expression and Clinicopathological Features and Categorical Combinations of HER-2, ER and PR in invasive ductal carcinomas.
| Characteristic | Negative | Low | Moderate | Strong | P value |
|---|---|---|---|---|---|
| Age (years) | |||||
| ≤ 50 (n=104, 58.1%) | 0 (0%) | 8 (7.7%) | 23 (22.1%) | 73 (70.2%) | 0.378 |
| > 50 (n=75, 41.9%) | 0 (0%) | 8 (10.7%) | 13 (17.3%) | 54 (72%) | |
| Histological grade | |||||
| I (n=3, 1.7%) | 0 (0%) | 0 (0%) | 1 (33.3%) | 2 (66.7%) | 0.042 |
| II (n=75, 41.9%) | 0 (0%) | 6 (8%) | 11 (14.7%) | 58 (77.3%) | |
| III (n=101, 56.4%) | 0 (0%) | 10 (9.9%) | 24 (23.8%) | 67 (66.3%) | |
| Lymph node metastasis | |||||
| Yes (n=54, 30.2%) | 0 (0%) | 2 (3.7%) | 13 (24.1%) | 39 (72.2%) | 0.232 |
| No (n=125, 69.8%) | 0 (0%) | 14 (11.2%) | 23 (18.4%) | 88 (70.4%) | |
| Tumour size | |||||
| Tis (n=1, 0.6%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (100%) | 0.042 |
| T1 (n=17, 9.5%) | 0 (0%) | 2 (11.8%) | 7 (41.2%) | 8 (47.1%) | |
| T2 (n=119, 66.5%) | 0 (0%) | 14 (11.8%) | 20 (16.8%) | 85 (71.4%) | |
| T3 (n=26, 14.5%) | 0 (0%) | 0 (0%) | 5 (19.2%) | 21 (80.8%) | |
| T4 (n=16, 8.9%) | 0 (0%) | 0 (0%) | 4 (25%) | 12 (75%) | |
| Categorical combinations | |||||
| Her2(+),Pr(-),ER(-) (n=48, 26.8%) | 0 (0%) | 3 (6.3%) | 7 (14.6%) | 38 (79.2%) | 0.12 |
| Her2(+),Pr(+),ER(-) (n=7, 3.9%) | 0 (0%) | 1 (14.3%) | 2 (28.6%) | 4 (57.1%) | |
| Her2(+),Pr(+),ER(+) (n=47, 26.3%) | 0 (0%) | 2 (4.3%) | 10 (21.3%) | 35 (74.5%) | |
| Her2(-),Pr(+),ER(+) (n=18, 10.1%) | 0 (0%) | 0 (0%) | 4 (22.2%) | 14 (77.8%) | |
| Her2(+),Pr(-),ER (+) (n=24, 13.4%) | 0 (0%) | 5 (20.8%) | 7 (29.2%) | 12 (50%) | |
| Her2(-),Pr(-), ER(-) (n=23, 12.8%) | 0 (0%) | 4 (17.4%) | 4 (17.4%) | 15 (65.2%) | |
| Her2(-),Pr(-), ER(+) (n=8, 4.5%) | 0 (0%) | 1 (12.5%) | 1 (12.5%) | 6 (75%) | |
| Her2(-),Pr(+),ER(-) (n=4, 2.2%) | 0 (0%) | 0 (0%) | 1 (25%) | 3 (75%) |